Group One Trading’s Vivos Therapeutics VVOS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-228
Closed -$650 8731
2025
Q1
$650 Hold
228
﹤0.01% 7246
2024
Q4
$978 Hold
228
﹤0.01% 6894
2024
Q3
$595 Hold
228
﹤0.01% 6373
2024
Q2
$506 Hold
228
﹤0.01% 6446
2024
Q1
$1.1K Sell
228
-160
-41% -$956 ﹤0.01% 6617
2023
Q4
$4.83K Buy
388
+379
+4,211% +$3.25K ﹤0.01% 6523
2023
Q3
$41 Hold
9
﹤0.01% 7510
2023
Q2
$109 Sell
9
-43
-83% -$421 ﹤0.01% 7507
2023
Q1
$446 Sell
52
-92
-64% -$2.01K ﹤0.01% 6920
2022
Q4
$1.45K Sell
144
-450
-76% -$6.58K ﹤0.01% 6745
2022
Q3
$10K Sell
594
-462
-44% -$14.1K ﹤0.01% 6516
2022
Q2
$34K Sell
1,056
-1,630
-61% -$67.7K ﹤0.01% 5894
2022
Q1
$180K Buy
2,686
+2,503
+1,368% +$164K ﹤0.01% 4907
2021
Q4
$10K Sell
183
-110
-38% -$8.86K ﹤0.01% 7361
2021
Q3
$30K Buy
+293
New +$30.8K ﹤0.01% 6921

Other funds holding VVOS

Group One Trading's VVOS Position: Q2 2025 in Review

Group One Trading sold out of Vivos Therapeutics (VVOS) in Q2 2025, closing a stake of 228 shares — an estimated $650 sold.

Group One Trading first reported a position in VVOS in Q3 2021 and held it in 15 quarters. The position peaked at $180K in Q1 2022. 19 funds tracked by Wall St. Rank hold VVOS as of Q2 2025.

  • Group One Trading reported no remaining Vivos Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Group One Trading sold 228 Vivos Therapeutics shares in Q2 2025, an estimated $650.
  • Group One Trading first reported a position in Vivos Therapeutics in Q3 2021 and held it in 15 quarters.
  • Group One Trading's Vivos Therapeutics position peaked at $180K in Q1 2022.
  • 19 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q2 2025.

Based on Group One Trading's 13F filing for Q2 2025, filed 14 Aug 2025.